Not all stem cells are created equal part 9

 

 

Stem cell 1

 

The cardiAMP Heart Failure trial, a randomized, double-blind pivotal study enrolling patients with ischemic cardiomyopathy, left ventricle ejection fraction 20% to 40%, is the first to incorporate a cell potency score in screening criteria. In addition to standard screening studies, including 6-minute walk distance, New York Heart Association heart failure classification and Minnesota Living with Heart Failure Questionnare, patients undergo screening  mini-bone marrow aspiration to measure surface marker expression and functional properties in an assay devised to identify  therapeutically  potent bone marrow stem cells. Patients meeting the potency assay requirement are randomized to transendocardial autologous bone marrow mononuclear cells or sham procedure. The goal is a high effective cell dose, that is, a high number of bone marrow cells [target 2×10(8)] isolated  from selected patients and administered with efficient intramyocardial delivery by  Helix/Morph injection system. The primary outcome is change in 6-minute walk distance adjusted for major adverse cardiovascular events at 12 months.

Advertisements

About azaleaazelia

A nice person... :)
This entry was posted in Tak Berkategori. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s